Study S001456

A Prospective, Multicenter, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07563699
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1; PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 24
Start: 2026-08-09
Primary completion: 2028-05
Lead sponsor: Mapi Pharma Ltd.
Conditions: Diabete Type 2
Interventions: DRUG:SG Depot 2 mg; DRUG:SG Depot 4 mg; DRUG:SG Depot 6 mg; DRUG:SG Depot 8 mg
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The rate of treatment-associated adverse events (AEs) [Through study completion, up to 28 weeks for each subject]
Plasma concentration of semaglutide [Through study completion, up to 28 weeks for each subject]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.